Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The Radiobiology of Radiopharmaceuticals

Seminars in Radiation Oncology(2020)10.1016/j.semradonc.2020.07.002Source: DataRank Database

The Radiobiology of Radiopharmaceuticals is a research paper published in Seminars in Radiation Oncology (2020). On theSindex it has a DataRank of 0. It has been cited 84 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access84 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 2.00)OA: greenTopics (21)Linked Datasets (16)DataCite Reuse (16)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Andrew Z. Wang ORCID,Susan J. Knox,Zachary S. Morris ORCID

Live enrichment

PubMed:33246632 PMC:PMC7990047 OpenAlex:https://openalex.org/W3108304255

NCI NIH HHS

Grant: P01 CA250972

NIH HHS

Grant: DP5 OD024576

NCI NIH HHS

Grant: U01 CA233102

FWCI

2.00

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: https://www.elsevier.com/legal/tdmrep-license

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7990047

publisherhttps://api.elsevier.com/content/article/PII:S1053429620300473?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1053429620300473?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.semradonc.2020.07.002

Fields of Study

Radioactive contamination and transferEffects of Radiation ExposureRadiopharmaceutical Chemistry and ApplicationsHumansLinear Energy TransferNeoplasmsRadiobiologyRadiometryRadiopharmaceuticals

MeSH Terms

HumansNeoplasmsRadiobiologyRadiometryLinear Energy TransferRadiopharmaceuticals

Keywords

MedicineRadiobiologyMedical physicsNuclear medicineRadiologyRadiation therapy

Sustainable Development Goals

SDG 0: Affordable and clean energy

Additional file 1 of Physiologically based radiopharmacokinetic (PBRPK) modeling to simulate and analyze radiopharmaceutical therapies: studies of non-linearities, multi-bolus injections, and albumin binding

10.6084/m9.figshare.25045484.v1figshare

10.6084/m9.figshare.25045484figshare

Additional file 1 of Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma

10.6084/m9.figshare.26749421.v1figshare

Additional file 1 of Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma

10.6084/m9.figshare.26749421figshare

Additional file 4 of Early and long-term responses of intestinal microbiota and metabolites to 131I treatment in differentiated thyroid cancer patients

10.6084/m9.figshare.26750537.v1figshare

Additional file 4 of Early and long-term responses of intestinal microbiota and metabolites to 131I treatment in differentiated thyroid cancer patients

10.6084/m9.figshare.26750537figshare

Additional file 3 of Early and long-term responses of intestinal microbiota and metabolites to 131I treatment in differentiated thyroid cancer patients

10.6084/m9.figshare.26750534figshare

Additional file 1 of Early and long-term responses of intestinal microbiota and metabolites to 131I treatment in differentiated thyroid cancer patients

10.6084/m9.figshare.26750528.v1figshare

Additional file 5 of Early and long-term responses of intestinal microbiota and metabolites to 131I treatment in differentiated thyroid cancer patients

10.6084/m9.figshare.26750540figshare

Additional file 6 of Early and long-term responses of intestinal microbiota and metabolites to 131I treatment in differentiated thyroid cancer patients

10.6084/m9.figshare.26750543figshare

Additional file 3 of Early and long-term responses of intestinal microbiota and metabolites to 131I treatment in differentiated thyroid cancer patients

10.6084/m9.figshare.26750534.v1figshare

Additional file 2 of Early and long-term responses of intestinal microbiota and metabolites to 131I treatment in differentiated thyroid cancer patients

10.6084/m9.figshare.26750531.v1figshare

Additional file 2 of Early and long-term responses of intestinal microbiota and metabolites to 131I treatment in differentiated thyroid cancer patients

10.6084/m9.figshare.26750531figshare

Additional file 1 of Early and long-term responses of intestinal microbiota and metabolites to 131I treatment in differentiated thyroid cancer patients

10.6084/m9.figshare.26750528figshare

Additional file 6 of Early and long-term responses of intestinal microbiota and metabolites to 131I treatment in differentiated thyroid cancer patients

10.6084/m9.figshare.26750543.v1figshare

Additional file 5 of Early and long-term responses of intestinal microbiota and metabolites to 131I treatment in differentiated thyroid cancer patients

10.6084/m9.figshare.26750540.v1figshare

The Radiobiology of Radiopharmaceuticals

FAIR Checklist

Authors (3)

Funding (3 grants)

Impact

Open Access

Topics

Linked Datasets (16)

Annotations (Europe PMC)